ES2878156T3 - Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes - Google Patents
Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes Download PDFInfo
- Publication number
- ES2878156T3 ES2878156T3 ES17728484T ES17728484T ES2878156T3 ES 2878156 T3 ES2878156 T3 ES 2878156T3 ES 17728484 T ES17728484 T ES 17728484T ES 17728484 T ES17728484 T ES 17728484T ES 2878156 T3 ES2878156 T3 ES 2878156T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- peripheral
- antibody
- lymphoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(NC=*CCC*)=O Chemical compound CCC(NC=*CCC*)=O 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2878156T3 true ES2878156T3 (es) | 2021-11-18 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17728484T Active ES2878156T3 (es) | 2016-05-30 | 2017-05-30 | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| ES21170716T Active ES2981046T3 (es) | 2016-05-30 | 2017-05-30 | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21170716T Active ES2981046T3 (es) | 2016-05-30 | 2017-05-30 | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (https=) |
| EP (2) | EP3916392B1 (https=) |
| JP (2) | JP7066639B2 (https=) |
| KR (1) | KR102416144B1 (https=) |
| CN (2) | CN115932265B (https=) |
| AU (1) | AU2017272608B2 (https=) |
| CY (1) | CY1124768T1 (https=) |
| DK (2) | DK3916392T3 (https=) |
| EA (1) | EA201892542A1 (https=) |
| ES (2) | ES2878156T3 (https=) |
| FI (1) | FI3916392T3 (https=) |
| HR (2) | HRP20240670T1 (https=) |
| HU (2) | HUE067450T2 (https=) |
| IL (1) | IL263103B2 (https=) |
| LT (2) | LT3465214T (https=) |
| MA (2) | MA45124B1 (https=) |
| MD (2) | MD3916392T2 (https=) |
| MX (2) | MX388502B (https=) |
| PL (2) | PL3916392T3 (https=) |
| PT (2) | PT3465214T (https=) |
| RS (2) | RS62155B1 (https=) |
| SG (2) | SG10201911958SA (https=) |
| SI (2) | SI3465214T1 (https=) |
| SM (2) | SMT202400204T1 (https=) |
| WO (1) | WO2017207574A1 (https=) |
| ZA (2) | ZA201808647B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| AU2020267823A1 (en) * | 2019-05-03 | 2021-11-11 | Incyte Corporation | Anti-CD19 therapy in patients having a limited number of NK cells |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| KR20220104176A (ko) * | 2019-10-31 | 2022-07-26 | 모르포시스 아게 | 순차적 항-cd19 요법 |
| WO2021259902A1 (en) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2026024668A1 (en) * | 2024-07-22 | 2026-01-29 | Abbott Laboratories | Method of determining a volume of a liquid in a sample |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| DE602007013068D1 (de) * | 2006-09-13 | 2011-04-21 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| MX2013005270A (es) * | 2010-11-15 | 2013-10-25 | Medimmune Llc | Terapia combinada para linfomas de limfocitos b. |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| WO2013090478A1 (en) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Predicting responsiveness to antibody maintenance therapy |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| CN107209187B (zh) * | 2014-07-11 | 2021-04-20 | 国立健康与医学研究所 | 用于诊断血液癌症的方法 |
-
2017
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 CN CN202211271570.5A patent/CN115932265B/zh active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2878156T3 (es) | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes | |
| AU2020374947C1 (en) | Anti-CD47 and anti-CD20 based treatment of blood cancer | |
| KR20220085796A (ko) | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 | |
| JP2026004466A (ja) | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 | |
| HK40065007A (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| HK40065007B (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| BR112018074603B1 (pt) | Método para identificar um sujeito tendo leucemia linfocítica crónica, e anticorpo anti-cd19 | |
| NZ788788A (en) | Methods for predicting therapeutic benefit of anti-CD19 therapy in patients | |
| HK40002753B (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| HK40002753A (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| EA040320B1 (ru) | Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19 |